Posted on

AIkido Provides Update on Use of Machine Learning in Drug Development Program

PR Newswire

NEW YORK , Aug. 6, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided and update on the use of Machine Learning in support of its antiviral platform with the University of Maryland Baltimore School of Medicine.  The Company stated:

(PRNewsfoto/AIkido Pharma Incorporated)

The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.  To support this goal, physics-based machine learning (ML) is being applied by SilcsBio LLC to accelerate the discovery of broad-spectrum antivirals.  These efforts are targeting the human SKI complex that is involved in the replication of RNA viruses from which multiple drug candidates have been identified and shown to be effective against SARS-CoV-2 as well as other coronaviruses, including MERS-CoV, Influenza viruses and the filoviruses Ebola and Marburg. Ongoing efforts involve further development of those drug candidates using the SILCS data-driven ML ligand optimization approach in conjunction with medicinal chemistry, biophysical characterization, and cell- and animal-based antiviral experimental evaluation. These collaborative efforts will yield novel chemical entities to be considered for investigational new drug (IND) status and clinical trials leading to therapeutic agents poised to take on the next global pandemic.

Alex MacKerell , Grollman-Glick Professor of Pharmaceutical Sciences and CSO, SilcsBio, LLC, stated, “SilcsBio’s machine learning algorithm combines physics-based simulations with a data-driven machine learning approach to iteratively improve the predictability of the ligand optimization process. In addition, our deep graph-based deep neural network allows screening of more than a billion compounds in a matter of days, allowing discovery of novel compounds much quicker than traditional approaches.  Towards addressing the global Covid-19 pandemic SilcsBio, LLC has partnered with AIkido Pharmaceuticals by applying its proprietary technology towards the development of novel broad-spectrum antivirals that will also be effective towards other viruses, including Influenza, Ebola and Marburg.”

Prof. MacKerell went on to say, “The success of these drug development efforts are based on the power of the SilcsBio technology to unlock hidden binding hotspots on novel antiviral drug targets, the ability to identify sites on those targets that alter the interactions between novel interacting antiviral proteins and the rapid development of optimal and effective drug leads against those targets that will define the next generation of novel antiviral agents.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

CisionView original content to download multimedia: https://www.prnewswire.com/news-releases/aikido-provides-update-on-use-of-machine-learning-in-drug-development-program-301350242.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

Delic Announces Ifetayo Harvey–Drug Reform Advocate and Founder and Board President of the People of Color Psychedelic Collective– to Speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a never been seen before, two-day immersive Edutainment experience for revolutionary thought, health & wellness and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, August 4, 2021 – Delic Holdings Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that

Ifetayo Harvey will serve as one of the event’s mainstage speakers. Meet Delic is the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Harvey is the Founder and Board President of the People of Color Psychedelic Collective, long-time advocate for promoting drug policies grounded in science, compassion, and human rights, as well as the Social Media Manager for Caring Across Generations, an organization which creates a new way to live well and age with dignity in America.

Harvey states, “I am excited to push the boundaries of how we talk and think about wellness in our society at Meet Delic. I want our society to truly value and create wellness for everyone.” During her tenure at The Drug Policy Alliance, which is the nation’s leading organization advocating to end the war on drugs, Harvey fought hard for people to no longer be punished for what they put in their bodies. This created a deep desire within Harvey to further champion that  individuals be given the sovereign right and choice to use alternative medicines such as psychedelics without fear and impunity.

The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

“It is an honor to have Ifetayo Harvey speak at our conference and bring her unique perspectives on health, life and culture to our attendees,” said Delic co-founder, Jackee Stang. “She is a powerful voice in the movement toward embracing psychedelic wellness and reform and her work to right many wrongs in the ‘war on drugs’ is remarkable.”

The twenty hours of panels and keynotes will include a broad array of topics such as: “How Psychedelics Can be Effectively Used for Physical Optimization,” “PTSD Reset and Recovery,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” microdosing, activism, sexuality, and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor

The recipient of numerous human rights and leadership awards, Mr. White will assist MINDCURE on its mission to revolutionize mental health treatments through the development and scaling of science-backed psychedelic medicines globally.

VANCOUVER, BC, Aug. 4, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased today to announce the addition of Jerry White as Advisor to the Company.

A social entrepreneur, author, and humanitarian activist, Mr. White is a Professor of Practice at the University of Virginia. He is known for leading high-impact campaigns worldwide. Mr. White is a recognized leader of the International Campaign to Ban Landmines and a co-recipient of the 1997 Nobel Prize for Peace. White is a Senior Ashoka Fellow, recognized for a lifetime of social entrepreneurship in service to humanity. When he was 20, he lost his leg to a landmine while hiking in northern Israel and later co-founded Survivor Corps, created by and for survivors to help victims of war rebuild their lives.

“I’m thrilled today to be joining MINDCURE as an advisor. The company’s ambition to improve access to mental health through new technologies and psychedelic medicines is timely and vital,” said Jerry White. “I believe that my own experience learning to build resilience for trauma recovery, as well as engaging large audiences to power global movements, will help MINDCURE and this industry advance revolutionary wellness worldwide.”

“Never shying away from audacious goals, driving transformational global movements, asking the toughest of questions, and translating them to strategy– this is what Jerry brings and why I am so thrilled to welcome him to the advisory board at MINDCURE,” said Kelsey Ramsden, President & CEO, MINDCURE. “It’s an honour to welcome a truly noble and humane impact strategist to our advisory board. I look forward to working with Jerry on our visionary strategy to build mental wealth worldwide.”

About Jerry White

Jerry White shares in the 1997 Nobel Prize for Peace awarded to the International Campaign to Ban Landmines. Known for leading high-impact campaigns, three of which led to international treaties. White has worked closely with the late Diana, Princess of Wales, and Her Majesty Queen Noor of Jordan. Later, under President Barack Obama, White served as U.S. Deputy Assistant Secretary of State, launching the Bureau of Conflict and Stabilization Operations, where he introduced data-driven diplomacy and advanced decision analytics to predict with high accuracy the outcomes of conflict and negotiations. A Senior Ashoka Fellow, he earned his BA with high honors from Brown University; an MBA from the University of Michigan; with theological study at Cambridge University and Honorary Degrees from the Mount Sinai School of Medicine in NYC, the University of Massachusetts, and Caledonia University in Glasgow. He is a Professor of Practice at the University of Virginia, teaching on Religion, Violence, and Strategy while offering strategic advice to impact-minded investors and philanthropists.

The Company also announces it has granted a total of 305,000 stock options to certain employees and consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable: 10,000 at a price of $0.415 per share, 45,000 at a price of $0.43 per share, and 250,000 at a price of $0.465 per share, and subject to the terms of the Plan.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business.  Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, performance or achievements contemplated by forward-looking statements made may be materially different from the results anticipated or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; or that MINDCURE will advance wellness worldwide.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Jonathan L. Robinson CFA, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

HAVN LIFE HARVESTS FIRST CROP OF PSILOCYBIN MUSHROOMS AT ITS JAMAICA FACILITY

HAVN Life will export to Delic Labs in Canada for quality control and testing. This makes HAVN Life the first in the Caribbean Community and Common Market to export psilocybin.

Vancouver, BC – HAVN Life Sciences Inc. (CSE : HAVN) (FRA: 5NP) (FSE: 5NP)  (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is proud to announce the harvest of its first crop of psilocybin-containing mushrooms from their growing and production facility in Jamaica.

Working with its partner, GMP manufacturer P.A. Benjamin in Kingston, the Company will export the harvested psilocybin to Canada where it will be tested for safety and quality control through its lab partner, Delic Labs.

“This is the moment we have been tirelessly working towards,” says HAVN Life CEO, Tim Moore. “We’ve been aggressively meeting the targets in our strategic roadmap and having this last piece in place with DELIC Labs will enable HAVN Life to become the first and top choice for product supply globally,“ he adds.

Founded by award-winning chemist, Dr. Markus Roggen, and University of British Columbia Professor, Dr. Glenn Sammis, Delic Labs is a federally-authorized psilocybin and cannabis research laboratory—one of a handful of licensed psilocybin research labs in Canada. Delic Labs is one of the leading facilities in the world focused on QA/QC and safety testing for psilocybin and other psychedelic compounds. HAVN Life’s partnership with Delic Labs will facilitate the supply of product to the Company’s research and clinical partners, marking a very important step in HAVN Life’s strategy to produce quality-controlled, standardized product for research and clinical trials in North America, the Caribbean Community and Common Market (CARICOM) and Europe.

“Delic Labs is delighted to partner with HAVN on some of the world’s first psilocybin mushroom testing. Our lab has significantly built out its analytical and research capabilities to offer quality and safety testing to the psychedelic industry.” says Dr. Markus Roggen. “Psilocybin mushrooms are exciting and challenging botanicals with major medical potential. We are honored to have HAVN’s trust as their quality and safety testing partner in such a ground-breaking new industry.”

With this first harvest, HAVN Life will be able to begin supplying product to partners around the world, establishing the Company as an early mover in the ability to supply companies with high-quality, naturally derived psilocybin as markets open up around the globe.

“Having been in Jamaica since March setting up the HAVN Labs facility, this first harvest feels celebratory after an intense period of work,” says Dr. Ivan Casselman, Chief Psychedelic Officer at HAVN Life. “We are now very focused on delivering product to our supply partners and developing our own APIs going forward,” he adds.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

About Delic Labs

Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

 

LinkedInFacebookTwitterEmailShare
Posted on

Delic Announces Aubrey Marcus, New York Times Best Selling Author and Founder/CEO of ONNIT to speak at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, a first-of-its-kind, immersive Edutainment experience for revolutionary thought, holistic and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, July 29, 2021 – Delic Holdings Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Aubrey Marcus will serve as one of the headline speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Marcus is the holistic health founder and former CEO of ONNIT, a New York Times Best-selling author of Own the Day, Own Your Life, host of the Aubrey Marcus podcast, which boasts over 50 million downloads on iTunes, as well as the founding member of Fit for Service, one of the world’s most vital transformational communities.

As a lifelong advocate of holistic health, Aubrey is most passionate about raising awareness for the benefits of psychedelic medicine. “Psychedelic medicines have been an inexorable part of my story for the last 22 years. I’m looking forward to sharing more of my story with everyone at the Meet Delic event,” stated Marcus.

The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

“It is an honor to have Aubrey Marcus speak at our conference and bring his unique perspectives on health, life and culture to our attendees,” said Delic co-founder, Jackee Stang. “He is an experienced psychonaut, successful entrepreneur and a true renaissance man and his presence at the event will be invaluable.”

Panels and keynotes will include a broad array of topics such as: “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “PTSD Reset and Recovery,” “How Psychedelics Can be Effectively Used for Physical Optimization,” microdosing, activism, sexuality, and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About DELIC Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of DELIC’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, DELIC is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of DELIC to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, DELIC has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although DELIC believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and DELIC does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

HAVN LIFE NATURAL HEALTH PRODUCTS NOW AVAILABLE ON AMAZON.CA

With FBA designation, the Company continues to grow its retail footprint by partnering with the world’s largest ecommerce site

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind,

is pleased to announce it has received FBA designation from Amazon.ca for the company’s new line of natural health products, which launched on June 3rd. The ecommerce giant now carries the full line of HAVN Life natural health products and ships anywhere in Canada.

“Having HAVN Life products available for purchase on Amazon.ca is a huge win for us,” says Tim Moore, CEO of HAVN Life. “The reach and scope of the platform is bar none, and we are thrilled to be visible through the Amazon network so we can help build and empower healthy communities,” he adds.

In addition to Amazon.ca, the HAVN Life natural health product line is available through their own ecommerce site, yourhavnlife.com, which ships products to both US and Canadian markets. The products are also available at Nesters Market and Choices Market retail locations throughout British Columbia. With a growing retail footprint, HAVN Life is increasing its revenue stream while reaching new markets and customers.

HAVN Life formulations are non-GMO, vegan, bioavailable, and naturally-derived from functional mushrooms and other plants and created with human optimization in mind. The natural health product line has been thoughtfully formulated with adaptogens and antioxidants to support overall brain health, with natural compounds that are proven to support memory, focus, energy, and overall cognitive function.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

 

LinkedInFacebookTwitterEmailShare
Posted on

Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave

HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave believes psychedelics are extremely safe, especially under medical supervision, but believes understanding HPPD will lead to a better understanding of these molecules as a whole

MIAMI, July 29, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch a series of studies to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD). Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. Ehave believes the key to widespread acceptance for psychedelics is a focus on the good as well as the bad, which is why we are investing in this series of studies on HPPD.

Ben Kaplan, CEO of Ehave, said, “We strongly believe there is a genetic predisposition to this condition and will be conducting a large-scale genetic analysis to isolate an individuals’ risk profile. Additionally, we plan on integrating a series of visual processing tests into our app to measure HPPD objectively.” Mr. Kaplan continued, “Harm reduction and prevention is extremely important when dealing with these powerful molecules. We want to be an industry leader in preventing negative side effects during treatment and believe this can be of benefit to the entire industry.”

Individuals with HPPD have recurring visual disturbances that only recall the part of the drug trip that involved visions. The way these flashbacks in HPPD affect a person’s vision can be frustrating and may cause anxiety. Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. Some people have different flashback experience. Instead of a pleasurable trip, they experience confusing visual effects, such as halos around objects, distorted sizes or colors, and bright lights that won’t fade.

People experiencing these disturbances may be entirely aware of everything else that’s happening. The interruption in your field of vision can be annoying, disturbing, and possibly debilitating. That’s why these symptoms may be unsettling or upsetting. If these visual disturbances occur frequently, you may have a condition called hallucinogen persisting perception disorder (HPPD). As many as 5% of LSD users report some version of HPPD and serious cases could be as frequent as 1 in every 100 users of psychedelics. HPPD is most commonly caused by LSD and Mushrooms, but also can be caused by MDMA, Cannabis, and even SSRIs. The market for an HPPD cure extends far beyond simple psychedelics. There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. Unlocking the genetic link will help point us towards treatment and a cure. The “Perception Restoration Foundation” a non-profit working on HPPD, will be releasing an in-depth documentary in the coming months to get the word out on the condition.

Mr. Kaplan added, “Let me be clear, psychedelics are extremely safe, especially when used under medical supervision. Understanding HPPD, however, will lead to a better understanding of these molecules as a whole.”

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Posted on

DELIC Labs President and CSO Dr. Markus Roggen to Speak at MJBizCon

Dr. Roggen to Address the “Cost of the Status Quo: An Economic Look at Extraction Optimization”, Thursday Oct 21, 2021at 2:00pm PT

Vancouver, British Columbia – July 27, 2021 – DELIC Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced Dr. Markus Roggen, President and CEO of its subsidiary DELIC Labs has been selected as a speaker at MJBizCon 2021. Dr. Roggen will lead a discussion on “Cost of the Status Quo: An Economic Look at Extraction Optimization,” Thursday October 21, 2021 at 2:00pm PT. DELIC Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. DELIC Labs serves as the engine for the DELIC platform, conducting research and developing innovative product lines and intellectual property (IP), including psilocybin vaporization technology for future distribution across the Company’s physical footprint and licensed psychedelic wellness clinics in the United States.

“Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs,” said Dr. Roggen, DELIC Labs President and CSO. “The major obstacle to realize profits from an extraction operation is the disconnect between the business and production teams. Cannabis extraction should not be viewed as a black art but a quantifiable scientific process. And modern process analytics will improve the production and profits.”

Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics,  metabolomic identification and process optimization. DELIC Labs is one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. DELIC Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world. DELIC Labs is applying for a Dealer’s License, and intends to eventually commercialize its psilocybin research and associated intellectual property (IP).

Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Delic Labs is one of a handful of research labs licensed for both cannabis and psilocybin in Canada. Delic Labs was initially founded as Complex Biotech Discovery Ventures by Dr. Roggen and Prof. Dr. Glenn Sammis in 2018, and rebranded after the sale to Delic Corp. Dr. Roggen received his M/Sci degree from Imperial College, London, UK in 2008. He then pursued his graduate degree in organic chemistry at the Federal Institute of Technology in Zürich (ETHZ), where he received his PhD in 2012. Dr. Roggen was awarded an DAAD postdoctoral fellowship to pursue further training in physical organic chemistry at The Scripps Research Institute in La Jolla in 2013-2014. He then entered the cannabis industry in 2014 and since has held executive positions in analytical and production companies. His research into process optimization and analytical methods has been recognized with a number of awards, ElSohley Award of the ACS, Cannabis Scientist Power List 2020 & 2021, 40 under 40 by Marijuana Venture Magazine among others. Dr. Roggen is also a trusted advisor and mentor to multiple startups, startup accelerators and organizations

About DELIC Labs (formerly Complex Biotech Discovery Ventures Ltd.)

DELIC Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, DELIC Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the DELIC Corp family, the leading psychedelic wellness platform, DELIC Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

About DELIC Corp, Inc.

DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

Investor Relations Contact

Daniel Southan-Dwyer

Corporate Development

dsd@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, information concerning listing on the Canadian Securities Exchange, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following: the ability to consummate the Proposed Transaction; ‎the ability to ‎obtain requisite regulatory and securityholder approvals and the satisfaction of ‎other conditions to the ‎consummation of the Proposed Transaction on the proposed terms and schedule; the ability to ‎satisfy the ‎conditions to the conversion of the Subscription ‎‎Receipts (as defined in the Previous Press Release); the potential impact of the announcement or consummation of the Proposed Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Proposed Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN UNITED STATES

Posted on

Mindset Files International Patent Application for its Novel Psilocybin Synthesis Method

‍Toronto, Ontario, July 27, 2021 – Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that it has filed an international patent application for its novel psilocybin synthesis method. The application claims the priority date of the Company’s previously filed United States Patent and Trade Office provisional application, filed on July 24, 2020.

The patent application covers Mindset’s Synthesis Process, a ground-breaking process to synthesize psilocybin and psilocin—two of the known active compounds in psychedelic mushrooms. This process enables faster psilocin and psilocybin synthesis compared to many of the established methodologies used today and has advantages over current processes that include: lower cost, milder reaction conditions, more convenient operations, easily obtained commercially available raw materials, suitability for multi-kilogram scale manufacturing, and lower environmental impact.

Malik Slassi, Mindset’s VP of Innovation commented, “Since filing our provisional patent application in July of 2020, we have made substantial progress towards demonstrating the commercial viability of our synthesis process. Earlier this year, we engaged a leading international contract development and manufacturing organization (“CDMO”) to complete optimization and scale-up of the process. To date, significant optimization work has been completed and we are now initiating a 100g pilot scale synthesis to be followed by a 1.0 kg batch of cGMP psilocybin using Mindset’s Synthesis Process. The large-scale cGMP synthesis batch is expected to be completed by the end of 2021.”

“We believe that our proprietary synthesis process is likely the most cost-effective method available in the marketplace today for cGMP grade psilocybin. The process strategically complements our next generation drug development programs and represents a significant potential market opportunity with near-term revenue potential. We anticipate that there will be significant demand for our cGMP psilocybin supply given the increasing number of trials and studies underway utilizing psilocybin,” added James Lanthier, CEO of Mindset.

Watch Mindset’s management team discuss the significance of this announcement:

https://www.youtube.com/watch?v=yfmIlGTw_4A.

The Company has engaged Pinnacle Capital Markets to provide digital marketing and awareness services at a cost of $4,500 per month for a six-month term.

‍About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is advancing its own proprietary therapeutics identified across its four novel families of psychedelic-inspired compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

‍Investor Contact:

Allison Soss/Tim Regan

KCSA Strategic Communications

Email: MindSet@kcsa.com

Phone: 212-896-1267/ 347-487-6788

‍Company Contact:

James Lanthier, CEO

Email: jlanthier@mindsetpharma.com

‍

Jason Atkinson, VP, Corporate Development

Email: jatkinson@mindsetpharma.com

Phone: 416-479-4094

‍Forward-Looking Information

‍This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized bywords such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30,2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NORITS REGULATIONS SERVICES PROVIDERHAVE REVIEWED OR ACCEPTRESPONSIBILITY FOR THEADEQUACY OR ACCURACYOF THIS RELEASE.

 

‍

Posted on

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

VANCOUVER, BC, July 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce it has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.

As first announced on July 13, 2021, MINDCURE has also filed patent applications for two routes of chemical synthesis of ibogaine. Both routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds. These two routes are currently under assessment to determine which will be the preferred method for further development.

Ibogaine is a psychoactive substance that can be found naturally in the roots of the iboga tree, which grows in Africa. Due to the psychoactive properties, ibogaine has traditionally been used for spiritual and ritual purposes among the Bwiti tribe in Gabon. Research has shown that ibogaine effects receptors known to have activity in pain, addiction, and neurodegenerative conditions, and it has also shown potential and is being studied for addictive disorders.1

MINDCURE’s synthetic production of ibogaine could provide access to a research and medicinal supply of pharmaceutical grade ibogaine. Successfully scaling up production of ibogaine would also create the opportunity for the drug to be used by MINDCURE’s research team, by other researchers conducting clinical trials, and eventually by clinicians providing psychedelic-assisted psychotherapy around the world.

“We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes,” said Kelsey Ramsden, President and CEO of MINDCURE. “We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of pharmaceutical grade product.”

“Ibogaine has the therapeutic potential to treat addiction and it shows promise in addressing other brain injuries as well,” said Joel Raskin, MINDCURE’s Chief Medical Officer. “Researchers need access to a standardized, high-quality supply of ibogaine that ensures consistent dosing and reliable results. Our goal is to be the company that provides this supply.”

_________________________________________________________________________________
Footnote 1:

 

He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J. 2006 Nov;20(13):2420-2. doi: 10.1096/fj.06-6394fje. Epub 2006 Oct 3. PMID: 17023388.

 

Marton S; González B; Rodríguez-Bottero S; Miquel E; Martínez-Palma L; Pazos M; Prieto JP; Rodríguez P; Sames D; Seoane G; Scorza C; Cassina P; Carrera I Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Front. Pharmacol, 2019, 10, 193. doi: 10.3389/fphar.2019.00193. [PubMed: 30890941]

 

Arena, E.; Dichiara, M.; Floresta, G.; Parenti, C.; Marrazzo, A.; Pittalà, V.; Amata, E.; Prezzavento, O. Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? Future Med. Chem. 2018, 10, 231–256.

_________________________________________________________________________________

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on Facebook, Twitter, and Instagram.

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, performance or achievements contemplated by forward-looking statements made may be materially different from the results anticipated or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; or that the Company will be successful in obtaining the patents applied for synthesizing ibogaine, or will be successful in synthesizing ibogaine or developing synthesized ibogaine for research, medical or commercial use.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

For further information: MINDCURE Investor Relations: investors@mindcure.com, 1-888-593-8995; Jonathan L. Robinson CFA, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001